When Almirall raked in 200 million euros ($211 million) via a share capital increase in June, the Spanish biopharma name-checked licensing opportunities as one potential way to splash its newfound cash. Four months later, the dermatology company appears to have found its first opportunity, signing a bispecific antibodies deal worth $210 million in biobucks..

当Almirall在6月份通过增资赚得2亿欧元（2.11亿美元）时，这家西班牙生物制药公司将许可机会视为挥霍新资金的一种潜在方式。四个月后，这家皮肤病公司似乎找到了第一个机会，签署了价值2.1亿美元的biobucks双特异性抗体交易。。

That money will give Almirall access to EpimAb Biotherapeutics’ Fabs-In-Tandem Immunoglobulin platform to generate, develop and commercialize bispecific antibodies. Almirall will have exclusive global rights to any resulting therapies from the collaboration in return for milestone payments totaling up to $210 million as well as a slice of the royalties..

这笔资金将使Almirall获得EpimAb Biotherapeutics的串联免疫球蛋白平台Fabs，以产生，开发和商业化双特异性抗体。Almirall将拥有合作产生的任何治疗的全球独家权利，以换取总计2.1亿美元的里程碑付款以及一部分版税。。

“This agreement with EpimAb is an important step forward and a great example of our ambition to develop new biologics in the dermatology field to ultimately bring innovation to patients,” Almirall Chief Scientific Officer Karl Ziegelbauer, Ph.D., said in the Oct. 12 release.

Almirall首席科学官Karl Ziegelbauer博士在10月12日的新闻稿中表示：“与EpimAb的这项协议是向前迈出的重要一步，也是我们在皮肤病领域开发新生物制剂以最终为患者带来创新的雄心壮志的一个很好的例子。”。

EpimAb’s technology generates bispecific antibodies using only the basic structural parts of monoclonal antibodies without adding any complex changes. So far, the Singapore-based company has focused its platform on the oncology space, with five clinical-stage assets in the works. The most advanced is EMB-01, a bispecific antibody designed to target both EGFR and cMet on tumor cells, which is in trials for breast and gastrointestinal cancers..

EpimAb的技术仅使用单克隆抗体的基本结构部分产生双特异性抗体，而不添加任何复杂的变化。到目前为止，这家总部位于新加坡的公司已将其平台专注于肿瘤学领域，并拥有五项临床阶段资产。最先进的是EMB-01，这是一种双特异性抗体，旨在靶向肿瘤细胞上的EGFR和cMet，正在进行乳腺癌和胃肠道癌的试验。。

“While we have made significant progress in utilizing our platform technology to develop a differentiated portfolio of bispecific antibodies in oncology, the potential of our platform in other areas such as immunology remains untapped,” EpimAb CEO Chengbin Wu, Ph.D., said in the release. “We believe Almirall is the partner of choice for this endeavor and look forward to exploring the use of our novel bispecific platform to offer additional treatment options for patients with immune-related disorders.”.

EpimAb首席执行官吴成斌博士在新闻稿中表示：“虽然我们在利用平台技术开发肿瘤双特异性抗体的差异化组合方面取得了重大进展，但我们平台在免疫学等其他领域的潜力仍未开发。”。“我们相信Almirall是这项努力的首选合作伙伴，并期待探索使用我们的新型双特异性平台为免疫相关疾病患者提供额外的治疗选择。”。

Today’s deal isn’t Almirall’s first dalliance with a bispecific-focused Asian company. Back in 2020, Almirall signed an agreement to access WuXi Biologics’ antibody platforms to discover multiple new bispecific antibodies.

今天的交易并不是艾米拉尔与一家专注于双特异性的亚洲公司的首次调情。早在2020年，Almirall就签署了一项协议，以访问无锡生物制品的抗体平台，以发现多种新的双特异性抗体。

The Barcelona-based company’s hunt to expand its pipeline comes as it continues to wait for European regulators to make a call on whether to approve the atopic dermatitis therapy lebrikizumab. When closing its share capital increase in June, Almirall said it would use part of the proceeds to “actively pursue and swiftly execute inorganic growth opportunities (including bolt-on acquisitions and in-licensing opportunities) that are currently under analysis.”.

这家总部位于巴塞罗那的公司寻求扩大其生产线之际，它仍在等待欧洲监管机构就是否批准特应性皮炎疗法lebrikizumab发出呼吁。Almirall在6月份完成增资时表示，将使用部分收益“积极寻求并迅速执行目前正在分析的无机增长机会（包括补强收购和许可机会）”。